Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Myelodysplastic Syndromes 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Neoplasms, Germ Cell and Embryonal 2Multiple Myeloma 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia 2Hepatoblastoma 2Glioblastoma 2Breast Neoplasms 2Brain Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Wilms Tumor 1Uveal Melanoma 1Skin Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Primary Malignant Peripheral Nerve Sheath Tumors 1Ototoxicity 1Oligodendroglioma 1Neoplasm Metastasis 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

temsirolimus 1ixabepilone 1Vorinostat 1Taxes 1Sirolimus 1Paclitaxel 1Irinotecan 1Erlotinib Hydrochloride 1Epothilones 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adult Solid Neoplasm × Vorinostat × 1 year × Clear all
NCT01281176 2026-04-20

High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
20 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡